Tag: NEXALIN

Nexalin Announces Peer-Reviewed Publication with Neuroimagina Data in Psychotherapy and Psychosomatics Hiahliahting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
Insomnia

Nexalin Study Shows Brain-Network Changes and Sleep Improvement in Chronic Insomnia

Nexalin Technology, Inc. announced the online publication of a peer-reviewed study in Psychotherapy and Psychosomatics reporting significant clinical improvement and measurable brain-network modulation in patients with chronic insomnia treated with the Company’s high-power 15 mA, 77.5 Hz stimulation approach. The paper was published online on April 20, 2026.  The study, titled: “Modulating […]

Continue Reading →
Nexalin Announces Pivotal HALO Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
Insomnia Technology

Nexalin’s HALO Clarity Trial to Support Planned De Novo FDA Submission Targeting Insomnia Market

Nexalin Technology, Inc. announced continued advancement toward its planned pivotal clinical trial evaluating HALO™ Clarity for the treatment of moderate to severe insomnia, designed to support Nexalin’s planned de novo submission to the U.S. Food and Drug Administration. The study is being conducted in collaboration with Lindus Health, a full-service clinical […]

Continue Reading →